25I-NBF

Canada lists 2C-phenethylamines in Schedule III of the Controlled Drugs and Substances Act. Item 35 covers the specified 1-amino-2-phenylethane structure when the amino group is substituted by benzyl groups, including benzyl groups substituted to any extent; this structural description covers 25I-NBF (N-(2-fluorobenzyl)-2C-I).

25I-NBF is prohibited as a new psychoactive substance under the NpSG's Annex 1 structural group for compounds derived from 2-phenethylamine. That group permits a phenyl ring with iodine and alkoxy substituents and an N-benzyl-substituted 2-aminoethyl side chain, within a 500-u molecular-mass limit. Section 3 prohibits trade, supply, manufacture, import/export/transit, acquisition, possession, and administration of an Annex 1 substance, subject to the statute's specified exemptions for recognised commercial, industrial, scientific, and authority uses.

The current consolidated controlled-substances regulation lists 25I-NBF as an individually named new psychoactive substance in Annex 3, point 6.1, and lists 25I-NBOMe separately under a different N-(2-methoxybenzyl) chemical name. Under the 2025 amendment, Btk. 459(1a) defines kábítószer for the relevant Btk. provisions to include substances in Annex 3 of the 78/2022 BM regulation. Consequently, unauthorized possession, acquisition, production, import, export or transit is covered by Btk. 178, while offering, transfer, placing on the market or dealing is covered by Btk. 176; the residual conduct-specific Btk. 184 offense covers offering or transfer to assist another person's pathological enjoyment (up to two years, or up to three years where made accessible to more than ten people) and placing on the market or dealing for that purpose (one to five years) where no other offense applies. For an Annex 3 point 6 substance, Btk. 461(5)-(7) sets a small quantity at pure active content not exceeding 2 g, significant quantity above 40 g, and especially significant quantity above 400 g; salt quantities are measured as base active content. Btk. 178(6) separately provides up to two years for consumption or acquiring/possessing a small quantity for consumption, and Btk. 180 provides a non-punishability route only if its admission, treatment/prevention-service and cooperation conditions are met; this is not general legalization.

The current MHLW designated-substances list identifies 25I-NBF by the exact N-(2-fluorobenzyl)-2-(4-iodo-2,5-dimethoxyphenyl)ethanamine identity and salts, at item 247, and classifies it as a designated substance. The PMD Act definition excludes substances already regulated as narcotics or psychotropics from the designated-substance category. The separately published current MHLW narcotics schedule contains no 25I-NBF, NBF, fluorobenzyl/iodo-dimethoxyphenethylamine, or matching 25I-NBF chemical-name entry. Under PMD Act Article 76-4, the designated substance may not be manufactured, imported, sold, transferred, possessed, purchased, received, or used for any purpose other than statutory medical等用途 (medical diagnosis, treatment or prevention and ministerially specified uses that do not risk harm to the human body). Thus ordinary non-medical possession, use, acquisition, transfer, manufacture, import, or sale is prohibited; this is not a prescription-only classification. For a non-business violation, Article 84(28) provides up to three years' 拘禁刑 (拘禁刑; the current statutory custodial penalty) or a fine up to ¥3,000,000, or both. Business manufacture, import, sale, transfer, or possession for sale/transfer (storage or display for that purpose) is separately covered by Article 83-9 and carries up to five years' 拘禁刑 or a fine up to ¥5,000,000, or both. These are statutory maximums and do not remove the limited medical等用途 exception.

The operative legal basis is the current Annex 2 to the Law On the Procedures for the Coming into Force and Application of the Criminal Law, rather than the expired Cabinet Regulation No. 847. The current schedule does not print 25I-NBF, NBF, 2C-I-NBF, Cimbi-21 or CAS 919797-21-0 as a standalone name. It instead places 2,5-dimetoksifeniletānamīni in List I paragraph 11 item 1 and captures any compound derived from 2-(2,5-dimethoxyphenyl)ethanamine where benzene hydrogens are substituted and/or one or two amino-nitrogen hydrogens are replaced by an unsubstituted or substituted alkyl group or nitrogen is incorporated in a ring. 25I-NBF is N-[(2-fluorophenyl)methyl]-2-(4-iodo-2,5-dimethoxyphenyl)ethanamine, with a 4-iodo/2,5-dimethoxy ring and N-(2-fluorobenzyl) group. The N-benzyl group is an N-substituent of the kind described by the Latvian amino-nitrogen alternative; the 4-iodo ring substitution independently satisfies the benzene-ring alternative. The Latvian rule therefore applies by structure, although the name does not appear verbatim in the schedule. List I is the prohibited category. Section 5 prohibits cultivation, production, manufacture, import, export, distribution, advertising, transport, storage, transfer for payment or without payment, acquisition, use and transit through Latvia of List I plants, substances and medicines. Section 7 permits a narrow State Agency of Medicines authorization for medical/veterinary scientific research, physical/chemical property determination and training; this is not an ordinary consumer, prescription or recreational exception. Criminal Law Section 253 provides up to three years or alternative sanctions for unauthorized manufacture, acquisition, storage, transportation or forwarding without disposal intent, and three to ten years (with optional confiscation and probation supervision up to three years) for a prior-agreement group or large amount. Section 253.1 provides two to eight years for disposal-intent handling or unlawful disposal, three to ten years for a prior-agreement group, and five to fifteen years (with optional confiscation and probation supervision up to three years) for an organized group, large amount, serious consequences or specified aggravated locations/victims. Section 253.2 provides short-term custody, probation supervision, community service or a fine for warned-person small-amount acquisition/storage without disposal intent or use, and up to three years or alternatives for small-amount disposal-intent handling or disposal. Section 254 provides fact-specific voluntary-surrender/reporting relief; it does not legalize possession or supply. The 0.02 g and 2 g values are criminal-law quantity thresholds, not lawful possession allowances.

25I-NBF falls within List IA's substance group for substances derived from 2-phenethylamine. The definition permits a phenyl ring bearing iodine and alkoxy substituents and an N-benzyl substituent with further permitted substitution, which encompasses the N-(2-fluorobenzyl) analogue. Article 2a prohibits import, export, preparation, processing, sale, supply, transport, possession, and manufacture of a substance in a List IA group, subject to the statutory exceptions.

Added to the Narcotic Drugs Punishments Act on January 26, 2016.²¹ Listed under Swedish Schedule I as a substance without accepted medical use, published by the Medical Products Agency in regulation HSLF-FS 2015:35.²¹

Ukraine's current consolidated List No. 2 of Table I expressly lists 25I-NBF (2C-I-NBF), with the chemical name N-[(2-fluorophenyl)methyl]-2-(4-iodo-2,5-dimethoxyphenyl)ethanamine. List No. 2 is headed as especially dangerous psychotropic substances whose circulation is prohibited; Resolution No. 600 added this named entry and it remains in the current consolidated list.

25I-NBF is a Class A controlled drug through the Schedule 2 generic definition for compounds structurally derived from the specified phenethylamine derivatives by N-benzyl substitution. The definition covers a benzyl substituent whether or not its phenyl ring is substituted, so the N-(fluorobenzyl) derivative falls within that provision. The Act also controls stereoisomers, esters, ethers, salts, and preparations of the specified substances.

Not federally scheduled at the national level. The state of Vermont has independently classified 25I-NBF as an illegal substance. Federal prosecution may still be possible under the Federal Analogue Act when sold for human consumption.³¹